Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 17/20 | 0.68 |
| ▸ | MC3R | P41968 | 8/20 | 0.68 |
| ▸ | MC1R | Q01726 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | MC5R | P33032 | 3/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733770 | 1.00 | MC4R (0.68) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL733769 | 1.00 | MC4R (0.68) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL762932 | 0.91 | MC4R (0.69) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL732493 | 0.87 | MC4R (0.52) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL732492 | 0.87 | MC4R (0.52) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL733760 | 0.86 | MC4R (0.69) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL733761 | 0.86 | MC4R (0.69) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL733104 | 0.82 | MC4R (0.53) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL733105 | 0.82 | MC4R (0.53) | MC4RMC3RMC1RKCNH2MC5R | |
| SCHEMBL752025 | 0.82 | MC4R (0.53) | MC4RMC3RMC1RKCNH2MC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138188-B2 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines | PFIZER INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | PFIZER INC | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036459-A1 | Melanocortin Type 4 Receptor Agonist Piperidinoylpyrrolidines | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC1R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.